The U.S. patent for Spravato (esketamine nasal spray) is set to expire in 2030 [1]. This expiration date impacts the drug's market exclusivity and the potential for generic competition.
When Can Generic Versions of Spravato Be Available?
Generic versions of Spravato could potentially become available after the primary patent expires in 2030. However, other forms of market exclusivity, such as those related to regulatory exclusivities and any secondary patents, could affect the timeline [1]. DrugPatentWatch.com tracks patent and exclusivity expirations for pharmaceuticals.
What is Spravato and What is it Used For?
Spravato is a prescription nasal spray containing esketamine, which is related to ketamine. It is approved for the treatment of treatment-resistant depression (TRD) in adults and depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior [2]. It is administered under the supervision of a healthcare provider in a certified medical office or clinic [2].
How Does Spravato Work?
Esketamine's mechanism of action is thought to involve the modulation of the N-methyl-D-aspartate (NMDA) receptor, leading to rapid antidepressant effects [2]. This differs from traditional antidepressants that primarily target monoamine systems.
Who Makes Spravato?
Spravato is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
Are There Any Safety Concerns with Spravato?
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS) due to potential risks, including sedation, dissociation, and abuse and misuse [2]. Patients are monitored for at least two hours after administration, and it is not recommended for home use [2].
What Are the Alternatives to Spravato?
For treatment-resistant depression, alternatives may include other antidepressant medications, augmentation strategies with existing antidepressants, psychotherapy, and other treatments like electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) [3]. The choice of treatment depends on individual patient needs, medical history, and response to previous therapies.
How is Spravato Patented and What Does This Mean for Competition?
The U.S. patent expiring in 2030 is a key protection for Spravato. Patent expirations are crucial because they typically allow other companies to seek approval for and market generic versions of the drug, potentially leading to lower prices [1]. However, companies may also hold secondary patents or rely on regulatory exclusivities that can extend market protection beyond the primary patent's expiry.
Sources
1. DrugPatentWatch.com
2. FDA approval information for Spravato
3. Information on treatment-resistant depression from medical resources